We are live on !
Find out more
Samsara BioCapital Portfolio holdings
AUM
$1.22B
Turnover
23.08%
1-Year Est. Return
242.83%
This Fund
S&P 500
This Quarter Est. Return
+14.97%
1 Year Est. Return
+242.83%
3 Year Est. Return
+1,579.88%
5 Year Est. Return
+1,852.28%
10 Year Est. Return
–
AUM
$1.22B
AUM Growth
+$188M
(+18%)
Cap. Flow
+$70.2M
Cap. Flow % of AUM
Cap. Flow %
5.76%
Top 10 Holdings %
Top 10 Hldgs %
90.48%
Holding
26
New
4
Increased
2
Reduced
5
Closed
2
Avg Time Held
1.9
years
Top 10 Avg Time Held
1.5
years
Top 20 Avg Time Held
1.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alamar Biosciences
ALMR
|
+$56.1M |
| 2 |
PBLS
Parabilis Medicines Inc
PBLS
|
+$15.4M |
| 3 |
Artiva Biotherapeutics
ARTV
|
+$8.7M |
| 4 |
Inventiva
IVA
|
+$5.38M |
| 5 |
Eloxx Pharmaceuticals
ELOX
|
+$5.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arcellx
ACLX
|
+$6.99M |
| 2 |
Jade Biosciences
JBIO
|
+$4.85M |
| 3 |
Palvella Therapeutics
PVLA
|
+$4.79M |
| 4 |
Upstream Bio Inc
UPB
|
+$3.2M |
| 5 |
X4 Pharmaceuticals
XFOR
|
+$1.79M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Scholar Rock
SRRK
$4.94B
| $379M | 31.16% |
6,897,652
| – | – |
2022 Q1
17 quarters
|
|
2
Alumis Inc
ALMS
$823M
| $179M | 14.67% |
6,345,219
| – | – |
2024 Q3
7 quarters
|
|
3
Mineralys Therapeutics
MLYS
$1.86B
| $158M | 13.01% |
5,871,018
| – | – |
2023 Q1
13 quarters
|
|
4
Septerna Inc
SEPN
$1.71B
| $105M | 8.66% |
3,149,128
| – | – |
2024 Q4
6 quarters
|
|
|
5
Alamar Biosciences
ALMR
$1.83B
| $67.2M | 5.52% |
+2,480,310
| New | +$56.1M |
2026 Q2
0 quarters
|
|
6
Neurogene
NGNE
$478M
| $54M | 4.44% |
1,717,127
| – | – |
2023 Q4
10 quarters
|
|
7
Kalaris Therapeutics
KLRS
$45M
| $52.4M | 4.31% |
12,881,175
-66,906
| -0.5% | -$348K |
2020 Q3
23 quarters
|
|
8
SpyGlass Pharma
SGP
$835M
| $47M | 3.86% |
2,109,953
| – | – |
2026 Q1
1 quarter
|
|
9
Sutro Biopharma
STRO
$188M
| $35.3M | 2.9% |
1,062,872
| – | – |
2018 Q4
30 quarters
|
|
|
10
Inventiva
IVA
$702M
| $23.9M | 1.96% |
6,314,805
+1,120,000
| +22% | +$5.38M |
2025 Q4
2 quarters
|
|
|
11
Jade Biosciences
JBIO
$871M
| $16.4M | 1.34% |
736,237
-232,561
| -24% | -$4.85M |
2025 Q2
4 quarters
|
|
|
PBLS
12
Parabilis Medicines Inc
PBLS
$3.14B
| $15.2M | 1.25% |
+556,044
| New | +$15.4M |
2026 Q2
0 quarters
|
|
13
vTv Therapeutics
VTVT
$107M
| $11.2M | 0.92% |
298,496
| – | – |
2021 Q4
18 quarters
|
|
14
Aquestive Therapeutics
AQST
$468M
| $10.4M | 0.85% |
2,500,000
| – | – |
2025 Q3
3 quarters
|
|
15
Nkarta
NKTX
$127M
| $9.9M | 0.82% |
3,507,666
| – | – |
2020 Q3
23 quarters
|
|
|
16
Artiva Biotherapeutics
ARTV
$285M
| $9.26M | 0.76% |
+954,861
| New | +$8.7M |
2026 Q2
0 quarters
|
|
17
Rani Therapeutics
RANI
$74.4M
| $7.88M | 0.65% |
10,369,159
+1,869,159
| +22% | +$1.66M |
2025 Q4
2 quarters
|
|
18
AgomAb Therapeutics NV
AGMB
$418M
| $7.79M | 0.64% |
600,000
| – | – |
2026 Q1
1 quarter
|
|
19
Abivax
ABVX
$7.67B
| $7.34M | 0.6% |
55,095
-1,486
| -3% | -$168K |
2025 Q3
3 quarters
|
|
|
20
X4 Pharmaceuticals
XFOR
$277M
| $6.52M | 0.54% |
1,395,587
-436,979
| -24% | -$1.79M |
2025 Q4
2 quarters
|
|
|
21
Eloxx Pharmaceuticals
ELOX
$44M
| $5.55M | 0.46% |
+400,000
| New | +$5.1M |
2026 Q2
0 quarters
|
|
22
Coherus Oncology
CHRS
$152M
| $4.8M | 0.39% |
3,428,571
| – | – |
2026 Q1
1 quarter
|
|
|
23
Upstream Bio Inc
UPB
$157M
| $2.45M | 0.2% |
353,717
-382,330
| -52% | -$3.2M |
2024 Q4
6 quarters
|
|
24
Gossamer Bio
GOSS
$52.5M
| $1.19M | 0.1% |
90,282
| – | – |
2023 Q3
11 quarters
|
|
|
25
DELISTED
Arcellx
ACLX
| – | – |
-60,873
| Closed | -$6.99M | – |
|
Similar funds
Samsara BioCapital's Q2 2026 Portfolio in Review
As of Q2 2026, Samsara BioCapital held 26 positions worth $1.22B, up 18% from $1.03B the previous quarter. Its ten largest holdings account for 90% of the portfolio.
Samsara BioCapital deployed $70.2M of net new capital in Q2 2026, opening 4 new positions and adding to 2 existing holdings. Its largest new stake was Alamar Biosciences: 2,480,310 shares worth $67.2M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Jade Biosciences, an estimated $4.85M trimmed.
- Samsara BioCapital's largest Q2 2026 buy was Alamar Biosciences: 2,480,310 shares worth $67.2M.
- Samsara BioCapital added most to Inventiva in Q2 2026, an estimated $5.38M increase.
- Samsara BioCapital's biggest Q2 2026 reduction was Jade Biosciences, cutting an estimated $4.85M.
- Samsara BioCapital fully exited Arcellx in Q2 2026, selling an estimated $6.99M.
- Samsara BioCapital's ten largest holdings make up 90% of its $1.22B portfolio in Q2 2026.
- Samsara BioCapital opened 4 new positions and closed 2 in Q2 2026.
- Samsara BioCapital's portfolio value rose 18% quarter-over-quarter to $1.22B.
Based on Samsara BioCapital's 13F filing for Q2 2026, filed 14 Aug 2026.